Meeder Asset Management Inc Concert Pharmaceuticals, Inc. Transaction History

Meeder Asset Management Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 11, 2020	SELL	$7.8 - $11.52 $14,781 - $21,830	-1,895 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$5.98 - $13.09 $6,183 - $13,535	1,034 Added 120.09%	1,895 $16,000
Q4 2019 Feb 13, 2020	SELL	$5.71 - $9.22 $2,575 - $4,158	-451 Reduced 34.38%	861 $8,000
Q3 2019 Oct 17, 2019	BUY	$5.88 - $12.35 $5,956 - $12,510	1,013 Added 338.8%	1,312 $8,000
Q2 2019 Aug 05, 2019	BUY	$9.44 - $13.12 $2,822 - $3,922	299 New	299 $4,000
Q1 2019 Apr 16, 2019	SELL	$12.07 - $17.54 $1,653 - $2,402	-137 Closed	0 $0
Q4 2018 Jan 17, 2019	BUY	$11.25 - $16.17 $1,226 - $1,762	109 Added 389.29%	137 $2,000
Q3 2018 Nov 02, 2018	SELL	$12.82 - $17.88 $80,471 - $112,232	-6,277 Reduced 99.56%	28 $0
Q2 2018 Jul 24, 2018	BUY	$16.83 - $21.66 $92,497 - $119,043	5,496 Added 679.36%	6,305 $0
Q1 2018 May 03, 2018	BUY	$19.24 - $28.03 $11,409 - $16,621	593 Added 274.54%	809 $19,000
Q4 2017 Feb 02, 2018	SELL	$13.96 - $29.05 $167 - $348	-12 Reduced 5.26%	216 $5,000
Q3 2017 Oct 20, 2017	BUY	$13.91 - $15.31 $3,171 - $3,490	228	228 $3,000

Ticker CNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,934,600
Description
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.